August is National Psoriasis Awareness Month
Access to FREE Psoriasis Medication During August, National Psoriasis Awareness Month
During the month of August, people with a certain type of psoriasis have the chance to receive a free medicine through Avenue to Access. The program is designed to help individuals with mild-to-moderate stable plaque psoriasis access to a FREE prescription-size tube of ZITHRANOL-RR® (anthralin, 1.2%) rapid release microcrystalline encapsulated cream.
Those who are interested in receiving a free tube of Zithranol-RR will need to see their doctor first. “The dermatologist should always be the first stop in psoriasis therapy,” said Dr. Joel Bernstein, a dermatologist and founder of Elorac, the pharmaceutical company offering the free psoriasis medicine.
Because psoriasis is a chronic disease, ongoing treatment can become very costly throughout a patient’s lifetime. According to a survey panel recently conducted by the National Psoriasis Foundation, approximately 44% of responders went without treatment for their psoriasis due to financial issues.
Psoriasis affects more than 7.5 million Americans and is a chronic disease that causes skin cells to grow at an accelerated rate. While psoriasis is not contagious, the stigma some feel can be debilitating.
The free medicine offer is through the month of August, which is also National Psoriasis Awareness Month.
For information on Avenue to Access and how to receive the free medicine for psoriasis, visit www.avenuetoaccess.com. For more information about psoriasis or to join the National Psoriasis Foundation, go to www.psoriasis.org.
About the National Psoriasis Foundation The National Psoriasis Foundation is the world's largest nonprofit organization serving people with psoriasis and psoriatic arthritis. Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education. For more information, call the Psoriasis Foundation, headquartered in Portland, Ore., at 800.723.9166, or visit www.psoriasis.org.
About Zithranol-RR®
Zithranol-RR® in indicated for the prescription treatment of mild to moderate stable plaque psoriasis and contains 1.2% microcrystalline encapsulated anthralin in a pearlized-green, aqueous cream. The anthralin in Zithranol-RR® is microencapsulated into a proprietary formulation of surface active crystalline polar lipids to provide for rapid release, as well as to reduce irritation and staining frequently observed with nonencapsulated anthralin preparations. Since Zithranol-RR®’s advanced delivery system rapidly releases anthralin into psoriatic plaques on contact with skin, Zithranol-RR® is especially useful for once-a-day, short contact (5-15 minutes) therapy. Zithranol-RR® contains no steroids or preservatives.
About Elorac
Elorac, Inc. is a privately held pipeline and marketing pharmaceutical company engaged in the discovery and development of novel products for the management of skin disorders. Elorac owns or licenses the rights to numerous treatments for various cutaneous diseases. Focusing exclusively on the management of skin disease, the company is poised to launch unique prescription products representing potentially significant improvement over current therapies.
Tags: